Ulcerative Colitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Ulcerative Colitis Pipeline Insight 2025' report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ulcerative Colitis Pipeline Landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ulcerative Colitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Ulcerative Colitis Treatment Landscape. Click here to read more @ Ulcerative Colitis Pipeline Outlook
Key Takeaways from the Ulcerative Colitis Pipeline Report
In April 2025, Merck Sharp & Dohme LLC announced a study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at week 52. Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12.
In April 2025, Janssen Research & Development, LLC announced a study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).
DelveInsight's Ulcerative Colitis pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ulcerative Colitis treatment.
The leading Ulcerative Colitis Companies such as Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
Promising Ulcerative Colitis therapies such as VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others.
Discover groundbreaking developments in Ulcerative Colitis therapies! Gain in-depth knowledge of key Ulcerative Colitis clinical trials, emerging drugs, and market opportunities @ Ulcerative Colitis Clinical Trials Assessment
Ulcerative Colitis Emerging Drugs Profile
Obefazimod: Abivax
Obefazimod is an oral small-molecule drug candidate in clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and has demonstrated anti-inflammatory activity in preclinical studies and in both Phase IIa and Phase IIb clinical trials. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ulcerative colitis.
ABBV-668: AbbVie
ABBV-668 is under development for the treatment of crohn's disease, unspecified immunological disorders and ulcerative colitis. The drug candidate acts by targeting receptor interacting serine/threonine protein kinase 1 (RIPK1). It is administered through oral route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.
TEV-48574: Teva Pharmaceutical
Anti-TL1A (TEV-'574) is a potentially best-in-class human IgG1 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15. TL1A signaling is believed to amplify inflammation and drives fibrosis associated with asthma and inflammatory bowel disease (IBD); thus, targeting TL1A with TEV-'574 may mitigate the over-active immune response in these conditions. Anti-TL1A (TEV-'574) is currently in Phase 2b clinical trials for the treatment of ulcerative colitis (UD) and Crohn's disease (CD), two types of inflammatory bowel disease. The safety and efficacy of anti-TL1A (TEV-'574) have not been reviewed by any regulatory authority. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.
SOR102: Sorriso Pharmaceuticals
SOR102 combines anti-TNF and anti-IL-23 vorabodies into a single dual-acting molecule a trypsin cleavable linker releases the monomers to independently engage their targets throughout intestinal tissue. SOR102 provides combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression. Overall benefits of dual targeting approach increased efficacy through blockade of different inflammatory mechanisms of IBD. Currently, the drug is in Phase I stage of its clinical trial for the treatment of ulcerative colitis.
The Ulcerative Colitis Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Ulcerative Colitis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis Treatment.
Ulcerative Colitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Ulcerative Colitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ulcerative Colitis market
Stay informed about the Ulcerative Colitis pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Ulcerative Colitis Unmet Needs
Ulcerative Colitis Companies
Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Intra-articular
Intraocular
Intrathecal
Intravenous
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Ulcerative Colitis Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Transform your understanding of the Ulcerative Colitis Pipeline! See the latest progress in drug development and clinical research @ Ulcerative Colitis Market Drivers and Barriers, and Future Perspectives
Scope of the Ulcerative Colitis Pipeline Report
Coverage- Global
Ulcerative Colitis Companies- Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
Ulcerative Colitis therapies- VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others.
Ulcerative Colitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Ulcerative Colitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
"Stay Ahead in Gastroenterology Research–Access the Full Ulcerative Colitis Pipeline Analysis Today! @ Ulcerative Colitis Drugs and Companies
Table of Content
Introduction
Executive Summary
Ulcerative Colitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Ulcerative Colitis– DelveInsight's Analytical Perspective
In-depth Commercial Assessment
Ulcerative Colitis Collaboration Deals
Late Stage Products (Preregistration)
Mirikizumab: Eli Lilly and Company
Drug profiles in the detailed report…..
Late Stage Products (Phase III)
Obefazimod: Abivax
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ABBV-668: AbbVie
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
SOR102: Sorriso Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Ulcerative Colitis Key Companies
Ulcerative Colitis Key Products
Ulcerative Colitis- Unmet Needs
Ulcerative Colitis- Market Drivers and Barriers
Ulcerative Colitis- Future Perspectives and Conclusion
Ulcerative Colitis Analyst Views
Ulcerative Colitis Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
5 days ago
- Globe and Mail
Chronic Insomnia Market Growth Projections 2023-2032: DelveInsight Analysis
The Key Chronic Insomnia Companies in the market include - Janssen Research & Development, Takeda, and others. The Chronic Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics. DelveInsight's 'Chronic Insomnia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Insomnia, historical and forecasted epidemiology as well as the Chronic Insomnia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Chronic Insomnia Market Report: The Chronic Insomnia market size was valued ~USD 333 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032) Among the seven major markets (7MM), the United States represented 67.3% of the total market size for Chronic Insomnia in 2021. In the 7 MM countries, there will be 5,697,127 cases of chronic insomnia that have been diagnosed as of 2021 Age plays a significant role in how the disease develops. The age group of 20 to 29 years saw the highest number of cases in the US in 2021 with 474,746. Following this, there were 421,996 instances in the US for each of the age groups of 30-39 and 40-49 years France had the greatest diagnosed prevalence of chronic insomnia among the European nations, with 890,539 cases. Germany came in second with 407,108 cases in 2021 Germany reported 207,625 instances of chronic insomnia in females and 199,483 cases in men among the EU5 nations in 2021 Key Chronic Insomnia Companies: Janssen Research & Development, Takeda, and others Key Chronic Insomnia Therapies: Seltorexant, Ramelteon and zolpidem, and others The Chronic Insomnia epidemiology based on gender analyzed that Chronic Insomnia is more prominent in females in comparison to males The Chronic Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics. Chronic Insomnia Overview Chronic insomnia is a long-term sleep disorder characterized by difficulty falling asleep, staying asleep, or waking up too early, occurring at least three times a week for three months or more. It leads to daytime fatigue, impaired concentration, mood disturbances, and reduced quality of life. Causes can include stress, medical conditions, medications, or poor sleep habits. Get a Free sample for the Chronic Insomnia Market Report: Chronic Insomnia Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Chronic Insomnia Epidemiology Segmentation: The Chronic Insomnia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalence of Chronic Insomnia Prevalent Cases of Chronic Insomnia by severity Gender-specific Prevalence of Chronic Insomnia Diagnosed Cases of Episodic and Chronic Chronic Insomnia Download the report to understand which factors are driving Chronic Insomnia epidemiology trends @ Chronic Insomnia Epidemiology Forecast Chronic Insomnia Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Insomnia market or expected to get launched during the study period. The analysis covers Chronic Insomnia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Chronic Insomnia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Chronic Insomnia Therapies and Key Companies Discover more about therapies set to grab major Chronic Insomnia market share @ Chronic Insomnia Treatment Market Chronic Insomnia Market Drivers Increasing Prevalence Personalization of therapies Chronic Insomnia Market Barriers Issues with diagnosis and poor knowledge Use of off-label drugs High economic burden Scope of the Chronic Insomnia Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Chronic Insomnia Companies: Janssen Research & Development, Takeda, and others Key Chronic Insomnia Therapies: Seltorexant, Ramelteon and zolpidem, and others Chronic Insomnia Therapeutic Assessment: Chronic Insomnia current marketed and Chronic Insomnia emerging therapies Chronic Insomnia Market Dynamics: Chronic Insomnia market drivers and Chronic Insomnia market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Chronic Insomnia Unmet Needs, KOL's views, Analyst's views, Chronic Insomnia Market Access and Reimbursement Table of Contents 1. Chronic Insomnia Market Report Introduction 2. Executive Summary for Chronic Insomnia 3. SWOT analysis of Chronic Insomnia 4. Chronic Insomnia Patient Share (%) Overview at a Glance 5. Chronic Insomnia Market Overview at a Glance 6. Chronic Insomnia Disease Background and Overview 7. Chronic Insomnia Epidemiology and Patient Population 8. Country-Specific Patient Population of Chronic Insomnia 9. Chronic Insomnia Current Treatment and Medical Practices 10. Chronic Insomnia Unmet Needs 11. Chronic Insomnia Emerging Therapies 12. Chronic Insomnia Market Outlook 13. Country-Wise Chronic Insomnia Market Analysis (2019–2032) 14. Chronic Insomnia Market Access and Reimbursement of Therapies 15. Chronic Insomnia Market Drivers 16. Chronic Insomnia Market Barriers 17. Chronic Insomnia Appendix 18. Chronic Insomnia Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
CBC
16-05-2025
- CBC
N.S. designates new special planning area near Blue Mountain-Birch Cove Lakes
The Nova Scotia government is trying to spur more new housing in the Halifax area by adding another piece of land to the list of areas fast-tracked for development, and calling on the city to start work on development plans for two areas. Colton LeBlanc, the minister for growth and development, announced Friday morning that he's designated 255 hectares of land west of Highway 102 between Kearney Lake Road and Lacewood Drive as a special planning area. The corridor of land abuts the Blue Mountain-Birch Cove Lakes area. LeBlanc also asked Halifax Regional Municipality to start secondary planning work for the Highway 102 area and the Sandy Lake special planning area. Secondary planning looks at infrastructure needs that include water, sewer and transportation. "What we'll see here is, over five, 10, 15 years, a controlled growth of housing in these two areas to help fill the gaps in our housing needs," LeBlanc told reporters. LeBlanc said both areas were identified for potential growth as far back as 2006. In the case of the Highway 102 corridor, developers have shown interest in the past, but the city refused to give approval to one, prompting a lawsuit. Vicki Elliott-Lopez, associate deputy minister of growth and development and chair of HRM's executive panel on housing, spoke alongside LeBlanc at a new conference Friday. "Good land, quite frankly, is really difficult to find for development these days," she said of the new designation. "It's getting more scarce, particularly around HRM and this will free up that opportunity." Development at Sandy Lake has been protested by several groups and individuals, including the Canadian Association of Physicians for the Environment. Members of the group have referred to the Sandy Lake area as Halifax's lungs and said it should be protected. LeBlanc said environmental concerns were looked at in and mitigation efforts "will be looked at." "Nova Scotians take great pride in our environment and our government … would not do anything to jeopardize our environment," LeBlanc said.
Globe and Mail
16-05-2025
- Globe and Mail
Anemia in Chronic Kidney Disease Market Set for Significant Growth and Innovation by 2034
Anemia in Chronic Kidney Disease (CKD), a common and debilitating complication resulting from reduced erythropoietin production and iron deficiency, continues to pose serious clinical challenges and an economic burden. DelveInsight's comprehensive report on the Anemia in CKD market sheds light on the evolving understanding and management of this condition, which affects a substantial proportion of patients with moderate to advanced CKD. With improved awareness and screening, earlier diagnosis and intervention are becoming more achievable, especially with the support of emerging biomarkers and treatment guidelines. Innovative therapies such as HIF-PH inhibitors and long-acting erythropoiesis-stimulating agents (ESAs) are shaping a dynamic treatment landscape aimed at improving hemoglobin levels with fewer side effects. DelveInsight's ' Anemia in Chronic Kidney Disease Market Report ' offers an in-depth analysis of the epidemiology, disease burden, and market outlook across key geographies, including the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report highlights current unmet needs, late-stage pipeline therapies, market drivers and barriers, and the key players transforming patient care, making it a vital resource for healthcare stakeholders and innovators in nephrology. Some of the Key Facts of the Anemia in Chronic Kidney Disease Market Report: • The anemia in chronic kidney disease is expected to grow at a significant CAGR by 2034. • In 2023, the United States recorded the highest number of prevalent Anemia in Chronic Kidney Disease (CKD) cases among the 7MM. • The U.S. also accounted for the highest number of treated cases of Anemia in CKD during the same year. • A higher prevalence was noted among individuals aged 60 and above compared to those under 60 in the U.S. • Males with CKD had a 30% higher risk of developing anemia compared to females. • Among the EU4 and the UK, Spain reported the lowest number of anemia in CKD cases in 2023. • In Japan, anemia was one of the most frequently documented outcomes, with prevalence rates ranging from 0% to 95%, depending on CKD severity and dialysis status. • In March 2025, the FDA expanded the approval of Furoscix to include the treatment of edema in patients with chronic kidney disease, including nephrotic syndrome. • In March 2025, scPharmaceuticals received FDA approval for a supplemental new drug application (sNDA) for Furoscix (furosemide injection). This approval expands the drug's use to treat edema in patients with chronic kidney disease (CKD), marking a significant advancement in scPharmaceuticals' portfolio for cardiorenal conditions. • In March 2025, the FDA approved an expanded indication for furosemide injection (Furoscix; scPharmaceuticals, Inc.) to treat edema in adult patients with chronic kidney disease (CKD), including nephrotic syndrome. The expanded treatment is expected to be available by April 2025. This approval follows the FDA's acceptance of the supplemental new drug application in July 2024. • In January 2025, the FDA approved a new indication for semaglutide to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, according to Novo Nordisk. • In November 2024, Unicycive Therapeutics (Nasdaq: UNCY) announced that the FDA has accepted its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC), with a PDUFA target action date set for June 28, 2025. If approved, OLC has the potential to significantly enhance the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients undergoing dialysis. • Leading companies in the anemia in chronic kidney disease market include Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, Acceleron Pharma, Celgene Corporation, and others. • Emerging therapies in the anemia in chronic kidney disease market include DDO-3055, SSS17, BCD-131, BCD-066, Erythropoietin polysialic, CHIP 2, PBI 1402, Sotatercept, and others. • The rising prevalence of anemia in chronic kidney disease, along with continuous advancements in therapeutic options, is fueling the demand for more effective treatment approaches. To know in detail about the anemia in chronic kidney disease market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Anemia In Chronic Kidney Disease Market Forecast Anemia in Chronic Kidney Disease Overview Anemia is a frequent and serious complication of Chronic Kidney Disease (CKD), arising as kidney function declines and the body's ability to produce adequate erythropoietin—a hormone essential for red blood cell production, diminishes. CKD impairs the kidneys' filtering ability, leading to the accumulation of waste and fluids, which further contributes to the onset of anemia. The condition becomes increasingly prevalent in advanced stages of CKD. In the United States, over 37 million adults are estimated to have CKD, and more than one in seven individuals with CKD also suffer from anemia. The risk intensifies as kidney function deteriorates, with nearly all individuals at end-stage kidney failure (when kidney function drops below 15%) experiencing anemia. Certain populations are more susceptible: individuals with CKD and diabetes are at higher risk of developing anemia earlier and in more severe forms. Additionally, people over the age of 60 are more likely to be affected. The progression of CKD-related anemia is typically gradual and may remain asymptomatic in its early stages, making early detection and management crucial for improving patient outcomes. Get a free sample of the anemia in chronic kidney disease market report with key insights and emerging therapies here: Anemia in Chronic Kidney Disease Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Anemia in Chronic Kidney Disease Epidemiology Segmentation: The anemia in chronic kidney disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by: • Total Prevalent Cases of Chronic Kidney Disease • Diagnosed Cases of Anemia in Chronic Kidney Disease • Age-Specific Prevalent Cases of Anemia in Chronic Kidney Disease • Total Prevalent Cases of Anemia in Chronic Kidney Disease • Total Prevalent Cases of Anemia in Different Stages of Chronic Kidney Disease • Treatable Cases of Anemia in Chronic Kidney Disease Download the report to understand which factors are driving anemia in chronic kidney disease epidemiology trends @ Anemia In Chronic Kidney Disease Epidemiology Forecast The anemia in chronic kidney disease drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the anemia in chronic kidney disease market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug. Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share. The report further delves into the anemia in chronic kidney disease pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies. Anemia in Chronic Kidney Disease Market Strengths • The availability of novel oral treatment options, such as daprodustat, offers more convenient and effective routes of administration for patients. • Active research and ongoing clinical trials are enhancing the understanding of the disease and driving innovation in therapeutic strategies. Anemia in Chronic Kidney Disease Market Weaknesses • Patients often struggle to recognize or differentiate the symptoms of anemia from CKD or other related conditions, leading to underreporting. • Healthcare providers, particularly in non-dialysis settings, frequently under-monitor hemoglobin levels and iron stores, resulting in delayed or suboptimal treatment initiation. Scope of the Anemia in Chronic Kidney Disease Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] • Key Anemia In Chronic Kidney Disease Companies: GlaxoSmithKline, Teva Pharmaceuticals, Cipla, Sun Pharmaceuticals, and others. • Key Anemia In Chronic Kidney Disease Therapies: DDO-3055, SSS17, BCD-131, BCD-066, Erythropoietin polysialic, CHIP 2, PBI 1402, Sotatercept, and others. • Anemia In Chronic Kidney Disease Therapeutic Assessment: Anemia in chronic kidney disease, currently marketed, and anemia in chronic kidney disease emerging therapies • Anemia In Chronic Kidney Disease Market Dynamics: Anemia in chronic kidney disease market drivers and anemia in chronic kidney disease market barriers • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies • Anemia In Chronic Kidney Disease Unmet Needs, KOL's views, Analyst's views, Anemia In Chronic Kidney Disease Market Access and Reimbursement To learn more about the key players and advancements in the anemia in chronic kidney disease treatment landscape, visit the Table of Contents 1. Anemia In Chronic Kidney Disease Market Report Introduction 2. Executive Summary for Anemia In Chronic Kidney Disease 3. SWOT analysis of Anemia In Chronic Kidney Disease 4. Anemia In Chronic Kidney Disease Patient Share (%) Overview at a Glance 5. Anemia In Chronic Kidney Disease Market Overview at a Glance 6. Anemia In Chronic Kidney Disease Disease Background and Overview 7. Anemia In Chronic Kidney Disease Epidemiology and Patient Population 8. Country-Specific Patient Population of Anemia In Chronic Kidney Disease 9. Anemia In Chronic Kidney Disease Current Treatment and Medical Practices 10. Anemia In Chronic Kidney Disease Unmet Needs 11. Anemia In Chronic Kidney Disease Emerging Therapies 12. Anemia In Chronic Kidney Disease Market Outlook 13. Country-Wise Anemia In Chronic Kidney Disease Market Analysis (2020–2034) 14. Anemia In Chronic Kidney Disease Market Access and Reimbursement of Therapies 15. Anemia In Chronic Kidney Disease Market Drivers 16. Anemia In Chronic Kidney Disease Market Barriers 17. Anemia In Chronic Kidney Disease Appendix 18. Anemia In Chronic Kidney Disease Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
